Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

Employers say healthcare spending is their greatest benefits challenge, yet many hesitate to take major cost-cutting steps, ...

The Centers for Medicare & Medicaid Services will begin holding closed-door meetings this week with patients who use the 15 ...

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...